ICON (NASDAQ:ICLR) stock fell 8% early Tuesday after it issued financial guidance for 2025. The clinical research ...

ICON Plc (ICLR), healthcare intelligence and clinical research company, on Tuesday reaffirmed its annual guidance. In addition, the ...

RBC Capital analyst Sean Dodge maintained a Buy rating on Icon (ICLR – Research Report) yesterday and set a price target of $263.00. The ...

ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts ...